Xsolla to Showcase New Pay Station, Mobile and New Solutions at Devcom and Gamescom 2022
15.9.2022 03:47:00 EEST | Business Wire | Press release
Xsolla, a global video game commerce company, is attending and presenting at Devcom and Gamescom 2022, the world’s largest computer and video games event, from August 22nd to August 28th in Cologne, Germany, EU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005128/en/
(Graphic: Business Wire)
Xsolla is hosting four informative speaking sessions at Devcom on August 22nd and 23rd, including a speaking session from President Chris Hewish. Additionally, Xsolla is exhibiting at Gamescom Hall 2.2, Booth #A-040-B-049, and Devcom booth #B1, where attendees can meet with Xsolla experts and preview the latest products and solutions designed to accelerate video game commerce in 2022.
“Having a platform to share Xsolla’s vision with those who are just as passionate about the gaming industry as we are is beyond exciting,” said Chris Hewish, President of Xsolla. “We look forward to speaking with and meeting people from across the globe who share our philosophy to help make gaming available for everyone. Whether you are a big AAA or an indie game just starting on your journey, we are here to help make your game and business a success.”
Xsolla will showcase and demonstrate its latest solution features and announcements at Devcom and Gamescom next week in Cologne.
Xsolla Pay Station
Xsolla’s Pay Station introduces significant updates to core functionality and is the only cross-platform branded payment experience for the video game industry. Features include an optimized user flow for an improved purchasing experience, a customizable user interface, streamlined mobile payments, and full support of mobile wallets worldwide.
“We are thrilled to be an early adopter of the new Payments Solution from Xsolla," said Mikhail Zakharenkov, Lead Producer at Nexters. "By implementing the new Pay Station into Hero Wars, we were able to customize the payment experience for our players and have seen more transactions and higher conversion rates since adding it to our web version for our players worldwide.”
For more information about Xsolla Pay Station, visit https://xsolla.events/gamescompaystation
Xsolla Web Shop for Mobile Games
Xsolla’s popular mobile solution now provides more opportunities for mobile game developers to power up their marketing efforts and engage users directly by offering expanded bundles, personalized online store experiences, and unique promotions personalized to players worldwide.
For more information about the Xsolla Web Shop, visit https://xsolla.events/gamescomwebshop
Xsolla Multi-Platform Publishing
Xsolla Multi-Platform Publishing is an advanced set of features for mobile game developers to support mobile game delivery to PC and the web. With a custom, branded client app and a seamless one-click authentication tool, mobile game developers can reach new gamers at a lower acquisition cost while increasing player loyalty and LTV. By bringing their game to new platforms, developers can grow their revenue potential by converting non-paying players into paying players and monetizing their games in underserved markets and new geographies.
For more information about the Xsolla Multi-platform Publishing solution, visit https://xsolla.events/gamescommpp
Xsolla Accelerator
A new funding program, Xsolla Accelerator, is now available for independent studios that seek games industry guidance and investment support early in their development cycle. Game developers can apply to educational programs led by industry mentors to help shape their game and content production and get the opportunity to receive a bridge fund of up to USD 100,000.00 to prepare them for the next stage of business valuations and investments. Accepted developers will also receive exclusive opportunities to connect with a global network of publishers and investors.
For more information about the Xsolla Accelerator, visit: https://xsolla.events/gamescommaccelerator
Xsolla Payouts
Whether you are a game developer willing to process payouts to user-generated content creators, an esports platform rewarding its players or a marketplace, this new solution streamlines mass payouts to hundreds or thousands of individuals. Xsolla Payouts optimizes operating efficiency by managing multiple contracts with users and content creators, holding tax interviews, facilitating tax reporting, and providing the most accurate account balance calculations.
For more information about Xsolla Payouts, visit: https://xsolla.events/gamescompayouts
Want to learn more about our powerful flagship commerce offerings that provide mobile developers a simple and customizable checkout experience? Please find below our scheduled speaker sessions and the opportunity to book a meeting with our team in person at Devcom and Gamescom!
Monday, August 22 | 12:00 p.m. - 12:30 p.m. CET [Add to Calendar]
SMART PAYMENT STRATEGIES FOR AMPLIFYING GAME REVENUE
Payments are the fundamental aspect of successful game revenue - join and learn how being payments savvy will help you reach more players in more territories, turn casual players into loyal paying users, and optimize your conversion rate, LTV, and ARPU.
Monday, August 22 | 3:00 p.m. - 3:30 p.m. CET [Add to Calendar]
READING MOBILE GAMING’S MONETIZATION TEA LEAVES
Learn how to maximize your customer base's engagement and augment your revenue stream. Mobile commerce expert Mikka Luotio will discuss best practices for creating a compelling Web Shop, what to sell, how to attract loyal customers, and how to amplify your conversion rate, LTV, and ARPU with this mobile-centric solution built for our changing market.
Tuesday, August 23 | 2:30 p.m. - 3:00 p.m. CET [Add to Calendar]
LET’S TALK GAME FUN-DING
Join industry veterans Rami Ismail and Justin Berenbaum for a fun, unfiltered fireside chat about the past, present, and future of game funding. Learn lessons from funding successes and horror stories, and get insights into the opportunities available to help your studio achieve its goals from concept to reality.
Tuesday, August 23 | 5:00 p.m. - 5:30 p.m. CET [Add to Calendar]
HEAVY INDIE GAMERS: WHO ARE THEY, AND HOW DO YOU SELL YOUR GAME TO THEM?
What kind of games interest indie gamers? What's the best way to sell your games to them? Join Chris Hewish, President of Xsolla, as he shares key findings from our research and equips indie game developers with the tools they need for success.
With Xsolla’s global game commerce experts, discover how they can help expand your video game commerce in the changing games industry.
For more information on how to attend speaking sessions and connect with Xsolla at Gamescom 2022, visit https://xsolla.events/gamescompr
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005128/en/
Contact information
Derrick Stembridge
Director of Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom